Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sapu Bioscience
San Diego, California, United Stateshk.marketscreener.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Sapu Bioscience develops first-in-class RNA therapeutics and small molecule drugs targeting cancer and infectious diseases. Its lead program, OT‑101, an anti-TGF-beta RNA therapeutic, has shown single-agent activity in relapsed/refractory cancer patients and activity against SARS-CoV‑2. The company holds rare pediatric designation for DIPG with OT‑101. A registrational Phase 2 trial for OT‑101 was initiated in partnership with Cromos Pharma[8][5].
- Therapeutic areas
- Infectious DiseasesOncology
- Modalities
- RNA therapySmall molecule
- Industry
- Biotech
02
Partnerships
Oncotelic TherapeuticsDragon Overseas Capital Ltd.GMP BiotechnologyCromos Pharma
Beyond the preview
Go deeper on Sapu Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sapu Bioscience.